- Citi sees good things ahead for Acceleron Pharma (XLRN +2.4%) in 2014, as analyst Yaron Werber reiterates a Buy rating.
- "In 2014 we expect multiple catalysts, extensive partnership with Celgene, and clinical data to continue to drive interest," Werber says, adding that Citi sees "data in both MDS and thalassemia [being] released at ASCO and EHA in June."
- Price target hiked to $50 from $30.
Citi lifts target on Acceleron Pharma
Jan 6 2014, 09:44 ET